secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xtant Medical Holdings, Inc. (XTNT)
CIK:        0001453593
Form:       8-K/A
Filed at:   2023-05-16T23:59:59+00:00
Accession:  0001493152-23-017793
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xtant completes $17M acquisition of Surgalign SPV's Coflex/CoFix product lines
------------------------------------------------------------------------------

- Purchase price $17M in cash; funded with cash on hand and $5M from existing term loan.
- Surgalign SPV 2021 revenue $17.8M, revenues in excess of direct expenses $8.0M.
- Pro forma 2021 net income $0.4M vs Xtant standalone net loss $4.8M; accretive.
- Acquired Coflex/CoFix FDA-approved for lumbar spinal stenosis, minimally invasive.
- Transaction closed Feb 28, 2023; abbreviated financials filed May 16, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453593/000149315223017793/0001493152-23-017793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453593/000149315223017793/form8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-017793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer